score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6174	311.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Putatively Actionable	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	0.0	0.0	0.0	BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	MEL-IPI_Pat49-Normal-SM-53U5W
Investigate Actionability - High	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.6134	313.0	0.0	0.0		Investigate Actionability - High	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Investigate Actionability - High	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability - High	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	0.0	0.0	0.0	BRAF p.V600M (Missense)	1.0	MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	MEL-IPI_Pat49-Normal-SM-53U5W
Investigate Actionability - High	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability - High	Ipilimumab	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498												0				 mutations per Mb		MEL-IPI_Pat49		
Investigate Actionability - High	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.K263*	0.4337	166.0	0.0	0.0		Investigate Actionability - High	AZD8186	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability - High	Pembrolizumab	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202-16.	https://doi.org/10.1158/2159-8290.CD-15-0283	Investigate Actionability - Low	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0	458.0	0.3362	1.0	PTEN p.K263* (Nonsense)	1.0	MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	MEL-IPI_Pat49-Normal-SM-53U5W
Investigate Actionability - High	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P124S	0.3268	153.0	0.0	0.0		Investigate Actionability - High	Selumetinib	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability - High	Selumetinib	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106						0	321.0	0.2087	1.0	MAP2K1 p.P124S (Missense)	0.0	MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	MEL-IPI_Pat49-Normal-SM-53U5W
Investigate Actionability - High	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.D951N	0.2871	202.0	0.0	0.0		Investigate Actionability - High	Ceritinib	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability - High	Ceritinib	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846						0	3.0	0.3333	0.0	ALK p.D951N (Missense)		MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	MEL-IPI_Pat49-Normal-SM-53U5W
Investigate Actionability - High	Preclinical			Somatic Variant	AKT3	Missense	p.S197N	0.2652	181.0	0.0	0.0		Investigate Actionability - High	MK-2206	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230												0	401.0	0.3416	1.0	AKT3 p.S197N (Missense)	0.0	MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	MEL-IPI_Pat49-Normal-SM-53U5W
Investigate Actionability - Low	FDA-Approved			Somatic Variant	TSC2	Missense	p.R917W	0.0317	126.0	8e-06	0.0		Investigate Actionability - Low	Everolimus	Targeted Therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Everolimus [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf												0	371.0	0.0054	0.9712	TSC2 p.R917W (Missense)		MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	MEL-IPI_Pat49-Normal-SM-53U5W
Investigate Actionability - Low	Preclinical			Somatic Variant	SMARCA4	Missense	p.R726H	0.0234	214.0	8e-06	0.0		Investigate Actionability - Low	VX-680	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098												0	488.0	0.0	0.9732	SMARCA4 p.R726H (Missense)		MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	MEL-IPI_Pat49-Normal-SM-53U5W
Biologically Relevant				Rearrangement	ATM	Fusion	ATM--CTSD			0.0	0.0																			0				ATM--CTSD Fusion		MEL-IPI_Pat49		
Biologically Relevant				Somatic Variant	MYC	Insertion	p.56_57insV	0.23399999999999999	47.0	0.0	0.0																			0	0.0	0.0	0.0	MYC p.56_57insV (Insertion)		MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	MEL-IPI_Pat49-Normal-SM-53U5W
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E37*	0.7	30.0	0.0	0.0																			0	0.0	0.0	0.0	CDKN2A p.E37* (Nonsense)		MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	MEL-IPI_Pat49-Normal-SM-53U5W
Biologically Relevant				Somatic Variant	RB1	Missense	p.P796S	0.2088	455.0	0.0	0.0																			0	248.0	0.1653	1.0	RB1 p.P796S (Missense)		MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	MEL-IPI_Pat49-Normal-SM-53U5W
Biologically Relevant				Copy Number	CHEK1	Deletion				0.0	0.0																			0				CHEK1 Deletion		MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	
Biologically Relevant				Copy Number	ROS1	Deletion				0.0	0.0																			0				ROS1 Deletion		MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	
Biologically Relevant				Copy Number	RET	Deletion				0.0	0.0																			0				RET Deletion		MEL-IPI_Pat49	MEL-IPI_Pat49-Tumor-SM-4DK2A	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																							0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat49		
Biologically Relevant				Mutational Signature	COSMIC Signature 7		0.832																							0				COSMIC Signature 7 (83%)		MEL-IPI_Pat49		
